Smith David Ross
Known title: DirectorCIK: 0001650274
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CRL Analyst Targets Rise After UBS Reinstates Coverage. Charles River Laboratories saw its average analyst price target increase to $305.00, driven by UBS reinstating coverage with a $357.00 target. This move follows reports of stabilizing demand and increased interest in animal model markets. The stock is currently trading below its 52-week high, with technical indicators showing support near $181.76.
Transaction History
| FTRE | ▲ Buy | Option Exercise | 6,598 | $0 | 7/20/2026 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 38,817 | $0 | 6/10/2026 | View on chart |
| FTRE | ▼ Sell | Tax Withholding | 18,244 | $298K | 6/10/2026 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 7,282 | $0 | 5/14/2025 | View on chart |
| FTRE | ▼ Sell | Tax Withholding | 2,185 | $10K | 5/14/2025 | View on chart |
| FTRE | ▲ Buy | Option Exercise | 6,354 | $0 | 7/18/2024 | View on chart |
| FTRE | ▼ Sell | Tax Withholding | 1,907 | $49K | 7/18/2024 | View on chart |
| CRL | ▲ Buy | Option Exercise | 3,846 | $421K | 3/3/2022 | View on chart |
| CRL | ▲ Buy | Option Exercise | 3,304 | $478K | 3/3/2022 | View on chart |
| CRL | ▲ Buy | Option Exercise | 1,815 | $326K | 3/3/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 3,825 | $1.1M | 3/3/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 2,606 | $736K | 3/3/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 1,289 | $365K | 3/3/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 858 | $244K | 3/3/2022 | View on chart |
| CRL | ▼ Sell | Open Market | 387 | $110K | 3/3/2022 | View on chart |
| CRL | ▲ Buy | Grant | 5,152 | $0 | 2/28/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 374 | $108K | 2/23/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 341 | $100K | 2/22/2022 | View on chart |
| CRL | ▼ Sell | Tax Withholding | 5,364 | $1.7M | 1/28/2022 | View on chart |
| CRL | ▲ Buy | Grant | 12,321 | $0 | 1/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Barclays Upgrades Fortrea, Boosts Target to $23
Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.
Barclays Upgrades Fortrea, Boosts Target to $23. Barclays has upgraded Fortrea Holdings to overweight and lifted its target price to $23. The upgrade follows a recent rise in the stock price and a mention of the company as an overrated pick in a Yahoo article. Analysts still see upside potential, with the average target of $21.04 and a 52‑week range that includes the new level. The stock’s high‑beta rating indicates it may continue to move sharply with market swings.